Results 141 to 150 of about 13,531,604 (176)

Knockdown of nicotinamide N-methyltransferase suppresses proliferation, migration, and chemoresistance of Merkel cell carcinoma cells in vitro. [PDF]

open access: yesHum Cell
Pozzi V   +13 more
europepmc   +1 more source

Beyond Nicotinamide Metabolism: Potential Role of Nicotinamide N-Methyltransferase as a Biomarker in Skin Cancers [PDF]

open access: yesCancers, 2021
Skin cancers (SC) collectively represent the most common type of malignancy in white populations. SC includes two main forms: malignant melanoma and non-melanoma skin cancer (NMSC). NMSC includes different subtypes, namely, basal cell carcinoma (BCC), squamous cell carcinoma (SCC), Merkel cell carcinoma (MCC), and keratoacanthoma (KA), together with ...
Annamaria Offidani   +2 more
exaly   +3 more sources
Some of the next articles are maybe not open access.

Related searches:

Novel Nicotinamide Analog as Inhibitor of Nicotinamide N-Methyltransferase

Bioorganic and Medicinal Chemistry Letters, 2018
Nicotinamide N-methyltransferase (NNMT) has been linked to obesity and diabetes. We have identified a novel nicotinamide (NA) analog, compound 12 that inhibited NNMT enzymatic activity and reduced the formation of 1-methyl-nicotinamide (MNA), the primary metabolite of NA by ∼80% at 2 h when dosed in mice orally at 50 mg/kg.
Takeshi Yura, Sven Ruf, Thomas Langer
exaly   +3 more sources

Nicotinamide N‐methyltransferase in nonmelanoma skin cancers

European Journal of Clinical Investigation, 2019
AbstractBackgroundSquamous cell carcinoma (SCC) and basal cell carcinoma (BCC) represent the most common forms of nonmelanoma skin cancers (NMSCs). Although successful treatment of these neoplasms is based on surgical excision, an increasing number of BCCs relapses and many SCCs display high rates of recurrence and metastasis.
Veronica Pompei   +10 more
openaire   +2 more sources

Adipose tissue as a source of nicotinamide N-methyltransferase and homocysteine

Atherosclerosis, 2009
Nicotinamide N-methyltransferase (NNMT) catalyses the conversion of nicotinamide to 1-methylnicotinamide and plays an important role in hepatic detoxification reactions. Here we show that, in addition to the liver, 3T3-L1 adipocytes as well as human and murine adipose tissue explants express high amounts of enzymatically active NNMT.
Monika, Riederer   +4 more
openaire   +2 more sources

Human nicotinamide N-methyltransferase pharmacogenetics

Pharmacogenetics, 1999
Nicotinamide N-methyltransferase (NNMT) catalyses the N-methylation of nicotinamide and structurally related pyridines. NNMT enzymatic activity in human liver varies over a five-fold range with a bimodal frequency distribution - raising the possibility of regulation by a genetic polymorphism. We set out to characterize molecular genetic mechanisms that
L, Yan   +2 more
openaire   +2 more sources

Glucose availability regulates nicotinamide N-methyltransferase expression in adipocytes

Life Sciences, 2020
Nicotinamide N-methyltransferase (NNMT) is a novel regulator of energy homeostasis in adipocytes. NNMT expression in adipose tissue is increased in obesity and diabetes. Knockdown of NNMT prevents mice from developing diet-induced obesity, which is closely linked to insulin resistance.
Franziska, Ehebauer   +2 more
openaire   +2 more sources

Nicotinamide N-methyltransferase: potential involvement in cutaneous malignant melanoma

Melanoma Research, 2018
Nicotinamide N-methyltransferase (NNMT) is an enzyme that catalyzes the N-methylation of nicotinamide and pyridine compounds, participating in xenobiotic and drug metabolism. Data on literature have evidenced a possible role of NNMT in many solid cancers, but no data are currently available in cutaneous melanoma.
Giulia, Ganzetti   +10 more
openaire   +2 more sources

Association of Nicotinamide-N-Methyltransferase Gene rs694539 Variant with Epilepsy

Molecular Neurobiology, 2015
Here, we report the association of the rs694539 variant of nicotinamide-N-methyltransferase gene with epilepsy in a case-control study of 215 patients with epilepsy and 239 healthy controls (χ (2) = 11.641, P = 0.003). The individuals with the GG genotype revealed protection against epilepsy (χ (2) = 5.866, P = 0.015, OR = 0.623, 95 % CI = 0.425-0.915),
Sazci, Ali   +3 more
openaire   +3 more sources

Home - About - Disclaimer - Privacy